Deletion of Letmd1 leads to the disruption of mitochondrial function in brown adipose tissue

Runjie Song1, Yaqi Du1, Peng Li1

  • 1State Key Laboratory of Agrobiotechnology, College of Biological Sciences, China Agricultural University, Beijing, 100193, China.

Biochimie
|July 11, 2022
PubMed

Insights

Loss of the human cervical cancer oncogene (HCCR-1), LETMD1, impairs brown fat thermogenesis and energy balance. This discovery offers new therapeutic targets for metabolic disorders.

Area of Science:

  • Mitochondrial biology
  • Metabolic disorders
  • Oncogene function

Background:

  • Human cervical cancer oncogene (HCCR-1), also known as LETMD1, is an outer mitochondrial membrane protein implicated in carcinogenesis.
  • LETMD1's role in metabolic regulation and energy homeostasis is not fully understood.

Purpose of the Study:

  • To investigate the function of Letmd1 in metabolic regulation, specifically in brown adipose tissue (BAT) thermogenesis.
  • To elucidate the molecular mechanisms by which Letmd1 influences mitochondrial function and energy balance.

Main Methods:

  • Generation of Letmd1-deficient mice.
  • Analysis of brown adipose tissue (BAT) and beige fat characteristics.
  • Assessment of thermogenesis, glucose tolerance, and insulin resistance.
  • Measurement of intracellular and mitochondrial calcium levels.
  • Evaluation of mitochondrial structure and function.

Main Results:

  • Loss of Letmd1 in mice resulted in BAT whitening, impaired thermogenesis in BAT and beige fat, cold intolerance, obesity, glucose intolerance, and insulin resistance.
  • Deletion of Letmd1 in BAT led to decreased mitochondrial and intracellular calcium levels.
  • Reduced intracellular calcium suppressed mitochondrial fission, disrupting BAT thermogenesis via altered mitochondrial structure and function.

Conclusions:

  • LETMD1 is essential for maintaining BAT thermogenesis and overall energy homeostasis.
  • LETMD1 regulates mitochondrial calcium levels, impacting mitochondrial dynamics and function.
  • LETMD1 represents a potential therapeutic target for metabolic disorders, repurposing insights from cancer oncogenes.